Overview

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

Status:
Completed
Trial end date:
2021-09-22
Target enrollment:
Participant gender:
Summary
This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
Phase:
Phase 1
Details
Lead Sponsor:
Presage Biosciences
Collaborators:
Fred Hutchinson Cancer Research Center
Northwell Health
Oregon Health and Science University
University of Washington
Treatments:
Aldesleukin
Antineoplastic Agents
Atezolizumab
Avelumab
Bortezomib
Docetaxel
Doxorubicin
Durvalumab
Entrectinib
Gemcitabine
Interferon alpha-2
Interferon-alpha
Interferon-gamma
Interferons
Ipilimumab
Nivolumab
Olaratumab
Pembrolizumab
Trabectedin